Invivyd - monoclonal antibodies

Invivyd

I’m ready to call it. This drug is incredible. Long Haulers need it. Just a couple of weeks along, I’m seeing what others w/ Long COVID report. These antibodies are powerful- WE NEED A TRIAL!!

My nightmare began in Jan ‘24. Today I feel Perfect
 
Mij said:
Invivyd

I’m ready to call it. This drug is incredible. Long Haulers need it. Just a couple of weeks along, I’m seeing what others w/ Long COVID report. These antibodies are powerful- WE NEED A TRIAL!!

My nightmare began in Jan ‘24. Today I feel Perfect
Click to expand...


I have to say I feel pretty skeptical about anti sars cov2 monoclonals as a long covid treatment. I just haven't seen much compelling evidence that viral persistance is a driver of symptoms.

And all the antiviral drugs that have been tried so far have had no efficacy.
 
Reply from an infectious disease doctor to a LC/ME/CFS patient:

Hi Rachel. For non-Covid related MECFS, of which I treat a large populous, I do not believe the monoclonal would be effective however I do take proactive approaches towards root cause, despite it being a bit more difficult, as it’s far more variable. You may DM re: consult.




For more discussion of Dr Michael Scoma, see the clinics thread: Dr Michael Scoma
 
Last edited by a moderator:
For what’s its worth, I’ve had long covid for 2 years beginning a week after my first covid infection resolved. My symptoms are primarily neurological (relatively severe) and cardio/circulatory. I’ve been essentially house bound with periods of being bed bound. I don’t have PEM or crushing fatigue (more so constant malaise and disabling neuro symptoms) I received Pemgarda 4 weeks ago and the improvement thus far is pretty amazing. Nothing I tried prior to Pemgarda had any meaningful impact. Below is a short synopsis.

Week 1: The infusion was uneventful. Tinnitus caused by LC flared during the infusion, which was the only side effect. On day 1, I felt a little fatigued. During the remainder of week 1, I felt better than I’ve felt in two years. Cardio/circulatory symptoms fully resolved and my head felt clearer and more normal than it’s felt in 2 years. Most of the odd neuro feelings that are difficult to put into words also subsided. Put simply, my brain felt like me again.

Week 2: I began feeling like I might be getting sick or experiencing some sort of mild immune activation. This flared LC symptoms (like an abbreviated relapse) and I felt somewhat worse then pre-Pemgarda for the remainder of the week, though nowhere near peak LC bad.

Week 3/4: Beginning with week 3, I started having periods of feeling entirely normal from the early afternoon onward. This trend has continued throughout week 4.

At this point, cardio/circulatory symptoms (pots, freezing hand and feet, high heart rate with minimal exertion, adrenalin surges/nausea) remain 100% gone. LC caused a complete loss of appetite. I lost 50lbs/200lbs and have been at my middle school weight as a 46 year old male for almost 2 years. I’ve gain 5lbs back in the last month, which is the first time I’ve regained weight. I developed near constant eye pain (dry/swollen) and loss of close up and night vision during the acute Covid infection. In the past week, my eyes are nearly normal once again. The worst of my neuro symptoms (acute suicidal ideation, psychosis like episodes, low oxygen like feeling in brain and partial loss of consciousness) have also subsided.

At this point, mornings are still rough as they’ve been throughout LC. I wake up feeling drugged or concussed. It typically takes an hour to force myself out of bed and then another hour or so before my head is clear enough to function. However, post-Pemgarda, once the awful morning issues clear, I feel pretty close to normal for the remainder of the day. All in, I would put it at a 75% improvement including resolution of all non-neurological symptoms.

Prior to Pemgarda, I was not a big believer in viral/antigen persistence. I would have put my money on something along the lines of Jonathan’s hypothesis. However, at least in my case, there is absolutely zero doubt in my mind that Pemgarda has done something very positive and it’s difficult to imagine what Pemgarda could be doing aside from binding to antigen.
 
Stuart79 said:
For what’s its worth, I’ve had long covid for 2 years beginning a week after my first covid infection resolved. My symptoms are primarily neurological (relatively severe) and cardio/circulatory. I’ve been essentially house bound with periods of being bed bound. I don’t have PEM or crushing fatigue (more so constant malaise and disabling neuro symptoms) I received Pemgarda 4 weeks ago and the improvement thus far is pretty amazing. Nothing I tried prior to Pemgarda had any meaningful impact. Below is a short synopsis.
Click to expand...
Mind if I ask how you were prescribed this medication? Isn’t it indicated for immunocompromised people as a Covid prophylaxis or treatment?
 
Jaybee00 said:
Mind if I ask how you were prescribed this medication? Isn’t it indicated for immunocompromised people as a Covid prophylaxis or treatment?
Click to expand...
With great determination, effort, and expense! In all seriousness, there are a handful of doctors who treat LC that are willing to prescribe it. Insurance is probably trickier to navigate, but I paid cash and skipped that hurdle. It’s around 7k if you shop around.
 
You might add bravery to your list too, in my opinion!
And not believing in it so much either, it must have been quite a leap of faith.
Sorry to hear the trouble you still experience in the mornings.
 
Release Details, September 4, 2025

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At Recover-TLC Workshop

Spear proposal reflects current evidence on monoclonal antibodies in treatment for LC and identifies VD2311 as a promising next-generation candidate for clinical study

Recommendations for a robust, comprehensive, translational study to evaluate the ability of VYD2311 to decrease circulation spike protein in eligible patients and to explore potential associated clinical benefits

Study design contemplates maintaining high antiviral antibody titers over an extended period to maximally suppress underlying chronic infection that may drive LC pathology

Dr. Amy Proal and David Putrino to present on behalf of SPEAR Study Group
 
Release Date: January 20, 2026

https://investors.invivyd.com/news-...spear-study-group-announce-plan-phase-2-study

  • Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injury
  • Participants to include people with Long COVID who demonstrate evidence of chronic infection or antigen persistence in a variety of tissues, and COVID vaccine-injured people including those who have demonstrated persistence of vaccine-delivered spike protein
  • Design includes multiple highly active antibody doses administered over the long term to assess the safety and potential clinical benefit of VYD2311 treatment, versus placebo
  • Millions of individuals continue to live with persistent and debilitating symptoms of Long COVID, underscoring the significant unmet need for development of effective treatment options
NEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) and the SPEAR Study Group today announced the plan to initiate a Phase 2 clinical trial evaluating monoclonal antibody VYD2311 in individuals with Long COVID or COVID vaccine injury.
 
The Phase 2 clinical trial is expected to be initiated by mid-2026 and to include the following features:

-Multiple high doses of highly active monoclonal antibody VYD2311, an investigational antibody that has demonstrated in vitro antiviral activity across all clinically recorded variants of SARS-CoV-2 tested since the original Wuhan strain, across many months of therapy

-Double-blind, placebo control

-Inclusion criteria designed to enroll people with demonstrated persistent infection or antigenemia, to the extent technologically possible

Clinical efficacy evaluations including functional performance tests and Patient-Reported Outcomes assessment (PROs) consistent across prior studies of Long COVID and other infection-associated chronic conditions and illnesses

“Not long after launching PEMGARDA® (pemivibart) for the prevention of COVID in certain immunocompromised people, we became aware of increasing, independent case reports of Long COVID treatment successes, as we previously noted,” said Marc Elia, Chairman of Invivyd’s Board of Directors. “These reports echo earlier work with other monoclonal antibodies and, along with continuously emerging reports and observations of chronic infection, give us confidence to explore this potential therapeutic signal in a prospective, placebo-controlled study, especially given the strong and broad antiviral activity we have observed with VYD2311. With the SPEAR Study Group, we believe we have the partnership of the leading minds in Long COVID and COVID vaccine injury, and we are looking forward to expanding our work radically for the benefit of people suffering from Long COVID, if we generate a meaningful signal of therapeutic benefit.”

Further details on the planned Phase 2 Long COVID trial of VYD2311 are expected to be made available in coming months, including details on www.clinicaltrials.gov when possible.
 
You must log in or register to reply here.
Back
Top Bottom